- Previous Close
0.6000 - Open
0.6000 - Bid 0.5900 x --
- Ask 0.6000 x --
- Day's Range
0.6000 - 0.6000 - 52 Week Range
0.5900 - 1.0600 - Volume
5,000 - Avg. Volume
14,420 - Market Cap (intraday)
27.297M - Beta (5Y Monthly) 0.59
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date Nov 15, 2024 - Nov 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Thiogenesis Therapeutics, Corp., a biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet pediatric medical needs. The company's lead product candidate comprises TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, other mitochondrial diseases, Rett syndrome, and pediatric non-alcoholic fatty liver diseases. Thiogenesis Therapeutics, Corp. is headquartered in Toronto, Canada.
www.thiogenesis.comRecent News: TTI.V
View More
Performance Overview: TTI.V
Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TTI.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TTI.V
View MoreValuation Measures
Market Cap
27.30M
Enterprise Value
27.70M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.74
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-61.53%
Return on Equity (ttm)
-98.58%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.49M
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
4.97M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.75M
Company Insights: TTI.V
TTI.V does not have Company Insights